BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the ...

Biosimilar trastuzumab marks a significant milestone ... lowering its UK prices to help hold on to much of its share in the IV market. Finally, other biosimilar companies are poised to join ...

That means the biosimilar competitors will be chasing an IV market which represents a relatively ... He said he expects Celltrion's trastuzumab will be up to 50% cheaper than Roche's subcutaneous ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Babies and children between the ages of three months and 11-years-old with pneumonia should be offered a three-day rather than five-day course of antibiotics, according to a new draft NICE guideline.